Skip to main content
$102.29 $1.33 (1.3%)

04:00 PM EDT on 10/22/21

Blueprint Medicines (NASDAQ:BPMC)

CAPS Rating: 4 out of 5

Current Price $102.29 Mkt Cap $6.0B
Open $101.13 P/E Ratio 17.12
Prev. Close $102.29 Div. (Yield) $0.00 (0.0%)
Daily Range $99.30 - $102.51 Volume 295,280
52-Wk Range $79.08 - $125.61 Avg. Daily Vol. 357,242

Caps

How do you think NASDAQ:BPMC will perform against the market?

Add Stock to CAPS Watchlist

All Players

37 Outperform
1 Underperform
 

All-Star Players

16 Outperform
0 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:BPMC Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

TMFEBCapital (96.86)
Submitted June 01, 2018

The company faces stiff competition from LOXO in developing RET targeting cancer treatment and LOXO has the pole position at ASCO over the coming days because of an oral presentation it's making. That could weigh down BPMC shares in the short-term,… More

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NASDAQ:BPMC VS S&P 500 (SPY)

NASDAQ:BPMC Summary

Fools bullish on NASDAQ:BPMC are also bullish on:

Fools bearish on NASDAQ:BPMC are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about BPMC.

Recs

0
Member Avatar TMFang4apples (55.41) Submitted: 6/28/2019 3:34:47 AM : Outperform Start Price: $90.60 NASDAQ:BPMC Score: -42.33

Array 2.0

Recs

0
Member Avatar freecapital (81.28) Submitted: 4/23/2019 5:03:06 AM : Outperform Start Price: $75.72 NASDAQ:BPMC Score: -21.18

fuma

Recs

1
Member Avatar TMFEBCapital (96.86) Submitted: 6/1/2018 10:50:57 AM : Outperform Start Price: $83.99 NASDAQ:BPMC Score: -44.34

The company faces stiff competition from LOXO in developing RET targeting cancer treatment and LOXO has the pole position at ASCO over the coming days because of an oral presentation it's making. That could weigh down BPMC shares in the short-term, but this company's RET data is also compelling. Additionally, its CEO is the former President of Algeta -- a company that developed Xofigo and was sold to Bayer. With proven management and a good shot at a game-changing approach to medicine, I think this one will be a one-time winner, despite the risk of a short-term drop.

Leaderboard

Find the members with the highest scoring picks in BPMC.

Score Leader

t0bes

t0bes (50.10) Score: +202.70

The Score Leader is the player with the highest score across all their picks in BPMC.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
km00nster 79.30 6/26/2015 Outperform 5Y $27.96 +264.84% +115.49% +149.35 0 Comment
gunterle 72.35 1/24/2017 Outperform 5Y $32.28 +216.02% +98.95% +117.06 0 Comment
jettyjett 65.96 5/30/2017 Outperform 5Y $35.50 +187.35% +87.57% +99.78 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. efarev 37.42 5/23/2017 Outperform 5Y $39.00 +161.56% +88.85% +72.72 0 Comment
PandaTears 22.98 7/26/2021 Outperform 5Y $85.15 +19.80% +3.15% +16.65 0 Comment
user400 < 20 2/25/2020 Outperform 5Y $65.22 +56.41% +40.23% +16.17 0 Comment
LohShiSan 96.43 5/11/2020 Outperform 5Y $62.68 +62.76% +55.67% +7.09 0 Comment
AppleMoonbeam 48.59 7/25/2017 Outperform 5Y $55.18 +84.88% +83.03% +1.85 0 Comment
TMFfuma102 88.27 4/14/2021 Outperform 5Y $93.12 +9.55% +9.77% -0.22 0 Comment
Bigcaps19 31.91 11/4/2019 Underperform 5Y $68.14 +49.71% +47.38% -2.33 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for BPMC.